---
title: "HWHG: Pregabalin sustained-release tablets have received the drug clinical trial approval notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263959550.md"
description: "HWHG's subsidiary Yichang HWHG Pharmaceutical recently received the \"Drug Clinical Trial Approval Notice\" approved by the National Medical Products Administration for Pregabalin Sustained-Release Tablets. This medication is primarily used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. This application aims to add new indications and expand its clinical use"
datetime: "2025-11-03T07:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263959550.md)
  - [en](https://longbridge.com/en/news/263959550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263959550.md)
---

# HWHG: Pregabalin sustained-release tablets have received the drug clinical trial approval notice

According to the Zhitong Finance APP, HWHG (600079.SH) announced that its controlling subsidiary, Yichang HWHG Pharmaceutical Co., Ltd. (referred to as "Yichang HWHG," in which the company holds an 80% stake), recently received the "Drug Clinical Trial Approval Notice" for Pregabalin Extended-Release Tablets issued by the National Medical Products Administration.

Pregabalin is a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels and reduces the release of neurotransmitters. Clinically, Pregabalin Extended-Release Tablets are mainly used to treat neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Yichang HWHG first obtained the "Drug Clinical Trial Approval Notice" for this product in 2023, with the initial approved indication being for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN). The current application for Pregabalin Extended-Release Tablets aims to add the indication for the treatment of postherpetic neuralgia (PHN)

### Related Stocks

- [600079.CN](https://longbridge.com/en/quote/600079.CN.md)

## Related News & Research

- [Bahrain International Airport begins gradual resumption of flights](https://longbridge.com/en/news/282125542.md)
- [Hengrui Pharmaceuticals Unit Gets Approval for Heart Failure Drug Trial](https://longbridge.com/en/news/282521960.md)
- [CSPC Pharmaceutical Gets China Nod for Clinical Trial of Tumor Drug](https://longbridge.com/en/news/282823913.md)
- [Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery](https://longbridge.com/en/news/282641629.md)
- [ZAWYA: Bahrain: Work on Bilaj Al Jazayer public beach renovation project begins](https://longbridge.com/en/news/282511886.md)